Across TCGA pan-cancer cohorts, ZNF691 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF691 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher ZNF691 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF691 expression acts as an unfavorable survival marker.
LGG and UCEC are the cancer types where ZNF691 Mutation most reproducibly stratifies survival.